(Updated October 2026. USD figures are converted at USD/JPY = 150 for reference.)
Japan’s ethical pharmaceutical wholesale market is led by four listed groups: Medipal Holdings, Alfresa Holdings, Suzuken and Toho Holdings. In 2023, Alfresa acquired Miyazaki Onsendo Shoten of Isahaya, Nagasaki, and Medipal took full ownership of Tohshichi of Sasebo, Nagasaki, bringing two independent regional wholesalers in Kyushu under the majors. In medical supplies and medical device distribution, two listed dealers, Olba Healthcare Holdings and DVx, combined in September 2026, and owner-run dealers in the Tohoku region have gathered under a shared holding company. Behind this activity are annual drug price revisions, wholesaler operating margins of about 1% or less, deteriorating hospital finances, and succession at owner-run companies. Foreign companies have entered adjacent fields such as dental distribution, dispensing pharmacies and medical supplies manufacturing, and foreign investors now hold large stakes in two of the four wholesale majors.
This article is written for corporate development and international business development teams at pharmaceutical companies, medical device manufacturers, healthcare distributors and investors that see Japan as an acquisition market, a source of partners, or a source of acquirers for their own businesses. It reviews Japan pharmaceutical distribution M&A through the market structure, the industry landscape, domestic consolidation, foreign capital in Japanese pharmaceutical and medical distribution, Japanese distributors’ and trading houses’ transactions abroad, the industry-specific factors acquirers examine, and the implications for overseas acquirers. In this article, “pharmaceutical wholesalers” refers to wholesalers of ethical (prescription) drugs, and “medical device dealers” refers to distributors of medical supplies and medical devices.
1. Market Structure — Thin Margins Under Government-Set Prices and Drivers of Consolidation
Market size
According to the Federation of Japan Pharmaceutical Wholesalers Associations (JPWA), pharmaceutical sales by its member companies were about ¥9.65tn (~USD 64bn) in fiscal 2023, and the federation had 68 member head offices as of September 1, 2025 (JPWA Guide 2025). Member companies employed 45,392 people, including 12,400 sales representatives (known in Japan as MS, marketing specialists), as of June 1, 2026, both lower than a year earlier (JPWA employee data).
For medical devices, the Ministry of Health, Labour and Welfare (MHLW) reports that in 2024 domestic production was ¥2,664bn (~USD 17.8bn), imports were ¥3,454bn (~USD 23.0bn), and domestic shipments were ¥4,708bn (~USD 31.4bn) (MHLW Pharmaceutical Industry Production Statistics). Imports exceed domestic production in Japan’s medical device market.
Profitability of pharmaceutical wholesalers
According to JPWA’s annual survey, the operating margin of member companies has ranged from 0.53% in FY2021 to 1.11% in FY2024.
| Fiscal year | Gross margin | SG&A ratio | Operating margin | Ordinary margin |
|---|---|---|---|---|
| FY2021 | 5.80% | 5.28% | 0.53% | 1.02% |
| FY2022 | 5.96% | 5.12% | 0.84% | 1.18% |
| FY2023 | 5.99% | 4.99% | 1.00% | 1.29% |
| FY2024 | 6.15% | 5.04% | 1.11% | 1.40% |
| FY2025 (preliminary) | 6.00% | 4.96% | 1.04% | 1.37% |
Source: JPWA, Business Overview of Pharmaceutical Wholesalers (2026 edition)
Gross margin is about 6% and the SG&A ratio about 5%. Operating profit is the narrow difference between the two, so any rise in logistics or personnel costs quickly compresses margins.
Business segments
Pharmaceutical wholesalers and medical device dealers differ by product in customers, pricing mechanisms and operating requirements. In M&A, the segments in which a company holds positions shape both the set of likely acquirers and the way they assess the business.
| Segment | Main customers | Pricing mechanism | Business characteristics |
|---|---|---|---|
| Ethical pharmaceuticals | Hospitals, clinics, dispensing pharmacies | The government sets reimbursement prices (NHI drug prices) and revises them based on market prices found in its price surveys. Delivered prices are negotiated between wholesalers and hospitals or pharmacies | National or regional logistics and inventory, information provided by sales representatives, and allocation of products in short supply |
| Medical supplies and devices | Hospitals, clinics | The government sets reimbursement prices for certain medical materials and revises them with each revision of medical fees. Other items are priced deal by deal | Products and customers are divided by clinical department and material type. Some dealers specialize in fields such as cardiovascular or endoscopy |
| Hospital procurement and logistics services | Hospitals | Contract-based | Outsourced management of in-hospital supply inventory (known in Japan as SPD) and group purchasing |
| Elderly-care and welfare equipment | Users, care providers | Some items are rented under long-term care insurance | Relationships with local users and care providers, and management of rental equipment |
Segments are classified by Syntax Partners for this article.
Five drivers of consolidation
- Annual drug price revisions and thin margins — Under the basic policy for drug pricing reform adopted in December 2016, Japan began off-year revisions in fiscal 2021, between the regular biennial revisions, and NHI drug prices have been revised every year since. The fiscal 2026 revision reduced drug prices by 4.02% on a drug-cost basis and 0.86% on a total medical-cost basis (MHLW, Overview of the FY2026 NHI Drug Price Revision). The outline of the fiscal 2026 drug pricing reform, approved by the Central Social Insurance Medical Council (Chuikyo), states that a revision will also be carried out in fiscal 2027. When Medical Ikkou Group, a wholesaler and pharmacy operator in Mie Prefecture, announced acquisitions of regional wholesalers, it stated that prices for ethical drugs are set by the government, that there are limits to passing on costs, and that it would respond through efficiency from greater scale (Case 6).
- Deteriorating hospital finances and rising logistics costs — In announcing their combination, Olba Healthcare Holdings and DVx cited lower prices and margins for medical devices following repeated reimbursement cuts, and higher logistics costs driven by labor shortages and fuel prices. Citing MHLW data, they noted that the operating margin of general hospitals fell from 1.4% in 2018 to minus 1.9% in 2023 (Case 5). As hospital finances deteriorate, dealers face pressure both to cut delivered prices and to make logistics more efficient.
- Supply stability — In MHLW’s survey, the number of ethical drugs under restricted shipment or suspended supply peaked at 4,726 in February 2024 and stood at 1,801 in July 2026, about 12% of the products surveyed (MHLW, survey on the supply status of ethical drugs). At a December 2024 meeting of Chuikyo’s drug pricing subcommittee, JPWA stated that drug shortages had not been resolved and called for the abolition of off-year price revisions, and it repeated that request at the subcommittee in August 2026. Among medical device dealers, Medirise Holdings and Akita Ika Kikaiten cited building a stable and efficient supply system as the purpose of their integration talks (Case 7).
- Portfolio decisions by large groups and shareholder demands — In 2023, Sumitomo Pharma sold its food-ingredient and chemical subsidiary to Medipal to concentrate on pharmaceuticals (Case 3). Such portfolio decisions by drugmakers create acquisition opportunities for wholesalers. Shareholders have also made demands on the listed wholesale majors over capital efficiency. Singapore-based 3D Investment Partners held 24.66% of Toho Holdings’ voting rights as of February 3, 2026, and according to Toho’s disclosure, proposed in October 2024 that Toho integrate with a peer. A gratis allotment of stock acquisition rights that Toho had put to its shareholders as a countermeasure, and that they approved in June 2026, was provisionally enjoined by the Tokyo District Court in September 2026; Toho has filed an objection. UK-based Silchester International Investors announced in September 2026 that funds it manages held about 11.96% of Medipal’s issued shares, and that it had requested an extraordinary general meeting with proposals including a special dividend of ¥122 per share and a share buyback of up to ¥95bn (~USD 633mn).
- Business succession — Japan’s Small and Medium Enterprise Agency estimated that by 2025 about 2.45 million owners of small and medium-sized enterprises would be over 70, that about half of them (1.27 million) would have no designated successor, and that if closures increased unchecked, a cumulative 6.5 million jobs and about ¥22tn (~USD 147bn) of GDP could be lost by 2025 (SME Agency, Current Analysis of Business Succession and M&A). Among pharmaceutical wholesalers and medical device dealers, Miyazaki Onsendo Shoten, founded in 1927, was sold by its owner’s holding company in 2023 (Case 1), and Makoto Medical Seiki, established in 1947, was sold by its owner’s holding company in 2024 (Case 4). In neither case did the seller disclose its reasons.
2. Industry Landscape
Japan’s four pharmaceutical wholesale majors
| Company | Headquarters | Consolidated revenue | Recent moves |
|---|---|---|---|
| Medipal Holdings | Chuo-ku, Tokyo | ¥3,817bn (~USD 25.4bn), FY2026/3 | Took full ownership of Tohshichi and acquired Sumitomo Pharma Food & Chemical in 2023. Took full ownership of PALTAC, a wholesaler of daily goods and OTC drugs, in 2026. Disclosed in September 2026 that a shareholder had requested an extraordinary general meeting |
| Alfresa Holdings | Chiyoda-ku, Tokyo | ¥3,104bn (~USD 20.7bn), FY2026/3 | Acquired Miyazaki Onsendo Shoten in 2023. In 2026, agreed to acquire Techno Suzuta of Nagasaki and Nagashima Medical Instruments, a maker of ear, nose and throat devices |
| Suzuken | Higashi-ku, Nagoya | ¥2,487bn (~USD 16.6bn), FY2026/3 | Took full ownership of medimo, a generative-AI medical documentation service, in February 2026. Its new medium-term plan aims to turn functions provided alongside wholesale into standalone fee-for-service businesses |
| Toho Holdings | Setagaya-ku, Tokyo | ¥1,553bn (~USD 10.4bn), FY2026/3 | 3D Investment Partners held 24.66% of voting rights as of February 3, 2026. In October 2026, confirmed after press reports that it had been considering acquiring shares in medical device maker PHC Holdings, and later that month announced that it had ended the review |
Consolidated revenue includes businesses other than ethical drug wholesale. The majors’ recent acquisitions extend beyond regional wholesalers into adjacent fields, including medical device manufacturing, food ingredients and chemicals, and digital services.
Regional and listed mid-size wholesalers
| Company | Headquarters | Consolidated revenue | Main territory and recent moves |
|---|---|---|---|
| Vital KSK Holdings | Setagaya-ku, Tokyo | ¥610bn (~USD 4.1bn), FY2026/3 | Formed in 2009 through a joint share transfer by Vital-Net (Sendai; Tohoku and Niigata) and KSK (Osaka; six prefectures of Kansai). In December 2025, KSK acquired Yachiyo Care Holdings, a seller and renter of elderly-care equipment |
| TSUMUGU HOLDINGS | Chuo-ku, Sapporo | ¥304bn (~USD 2.0bn), FY2026/3 | Holding company formed in 2006 by the pharmaceutical wholesaler Hokuyaku and the medical device dealer Takeyama. Renamed from Hokuyaku Takeyama Holdings on September 29, 2026 |
| Medical Ikkou Group | Tsu, Mie | ¥55.0bn (~USD 367mn), FY2026/2 | Listed operator of dispensing pharmacies, its main business, and pharmaceutical wholesale. Between 2024 and 2026, acquired small wholesalers in Kanto and Shikoku and a wholesale division in Kyushu (Case 6) |
Of Medical Ikkou Group’s consolidated revenue, sales to external customers were ¥26.3bn (~USD 175mn) in dispensing pharmacies and ¥19.4bn (~USD 129mn) in pharmaceutical wholesale.
Listed medical device dealers
| Company | Headquarters | Consolidated revenue | Main fields and recent moves |
|---|---|---|---|
| Ship Healthcare Holdings | Suita, Osaka | ¥718bn (~USD 4.8bn), FY2026/3 | Four segments: Total Pack Produce (bulk procurement of medical equipment for hospitals), Medical Supply (revenue ¥510bn, ~USD 3.4bn), Life Care and Dispensing Pharmacy. Acquired Konishi Kyowa Holding of Osaka in 2016 |
| Medius Holdings | Chiyoda-ku, Tokyo | ¥302bn (~USD 2.0bn), FY2026/6 | Built around Kurihara Iryokikaiten (Gunma) and Kyowa Ika Kikai (Shizuoka); has acquired dealers in Hokuriku, Tokyo, Kyoto, Hokkaido and Yamanashi |
| Olba DVx Healthcare | Okayama | ¥126.6bn (~USD 844mn), FY2026/6, before the combination | On September 1, 2026, Olba Healthcare Holdings took full ownership of DVx (FY2026/3 revenue ¥56.0bn, ~USD 373mn) through a share exchange and changed its name |
Listed medical device dealers have expanded their territories by acquiring regional dealers. Medius acquired Mitas of Fukui in 2018, Active Medical of Tokyo in 2020, Sano Kikai of Kyoto in 2021, Noah International of Hokkaido (through a subsidiary) in 2022 and Makoto Medical Seiki of Yamanashi in 2024.
Distribution companies within large groups
Distribution companies held by pharmaceutical makers or by groups in other industries have been sold to wholesalers and dealers. Sumitomo Pharma Food & Chemical, a subsidiary of Sumitomo Pharma, was sold to Medipal (Case 3), and Active Medical, a subsidiary of the care provider Active Care, was sold to Medius. A subsidiary of a listed dealer can also move to another regional group: Akita Ika Kikaiten, a Medius subsidiary, has signed a basic agreement to begin discussions on integrating with Medirise Holdings, a holding company of dealers in Tohoku (Case 7).
Owner-run companies
Many non-listed pharmaceutical wholesalers and medical device dealers are owned by founding families or their holding companies. Among the cases in this article, Miyazaki Onsendo Shoten (sold by the owner’s holding company; Case 1), Makoto Medical Seiki (likewise; Case 4), Sano Kikai (79.7% held by its president), and the regional wholesalers acquired by Medical Ikkou Group (acquired from individual shareholders; Case 6) were all owner-run. In Tohoku, three dealers, Shibata Intec (Sendai), Kyoritsu Ika Kikai (Morioka) and Legit Medical (Aomori), combined under Medirise Holdings through share exchanges in April 2024. Non-listed companies disclose limited information, and identifying them requires research beyond public databases.
Concentration in Kansai
Of the companies covered in this article, KSK (Chuo-ku, Osaka), Ship Healthcare Holdings (Suita, Osaka), Konishi Kyowa Holding (Chuo-ku, Osaka, at the time of its 2016 acquisition), Sano Kikai (Minami-ku, Kyoto), Sumitomo Pharma Food & Chemical (Kita-ku, Osaka, at the time of its 2023 acquisition) and Daishin Trading (Osaka, at the time of the 2007 sale of its implant business; Case 8) are headquartered in Osaka or Kyoto prefectures.
3. Domestic Consolidation — Regional Wholesalers, Carve-Outs and Dealer Integration
Case 1: Alfresa Holdings and Miyazaki Onsendo Shoten (2023), Techno Suzuta (2026) — Regional wholesalers acquired from an owner’s holding company
In January 2023, Alfresa Holdings agreed to acquire all shares of Miyazaki Onsendo Shoten, a pharmaceutical wholesaler in Isahaya, Nagasaki, from Onsendo, the owner’s holding company, and completed the acquisition on February 28. Founded in January 1927, Miyazaki Onsendo Shoten wholesales ethical drugs and diagnostic reagents and equipment, and reported revenue of ¥22.2bn (~USD 148mn) for the fiscal year ended February 2022, before its businesses other than ethical drug wholesale were transferred to Onsendo in August 2022. Alfresa stated that the purpose was to enhance corporate value by strengthening its business base in Kyushu. The price was not disclosed.
In February 2026, Alfresa agreed to acquire all shares of Techno Suzuta, a wholesaler of diagnostic reagents and medical devices in Nagasaki City, from the same Onsendo, aiming to expand its wholesale business in medical, research and welfare products and to strengthen distribution of medical products in Kyushu. Miyazaki Onsendo Shoten is scheduled to merge into Alfresa Corporation, Alfresa Holdings’ operating subsidiary. Completion of the Techno Suzuta acquisition had not been confirmed at the time of writing.
This transaction shows that (i) a regional wholesaler in Kyushu was sold by its owner’s holding company to a wholesale major, (ii) before the sale, businesses other than ethical drug wholesale were moved to the owner’s side, so that only the wholesale business was transferred, and (iii) the acquirer later agreed to acquire a diagnostics and device wholesaler from the same owner.
Case 2: Medipal Holdings and Tohshichi (2023) — From business alliance to full ownership
Medipal Holdings formed a business alliance in 2008 with Tohshichi, a pharmaceutical wholesaler in Sasebo, Nagasaki, and held 13.4% of its shares. In February 2023, Medipal agreed to take full ownership of Tohshichi through a share exchange, issuing 580 Medipal shares for each Tohshichi share, and the exchange took effect in April 2023. Tohshichi reported revenue of ¥27.2bn (~USD 181mn) for the fiscal year ended November 2022, from ethical drug wholesale, medical devices, care support services and property leasing. Medipal cited the strengthening of its business base in Nagasaki and Saga and of its distribution infrastructure in Kyushu.
This transaction shows that (i) the relationship between a wholesale major and a regional wholesaler began with a business alliance and a minority stake, and led to full ownership 15 years later, and (ii) the acquirer used its own shares as consideration through a share exchange. Together with Case 1, two regional wholesalers in Kyushu joined wholesale majors in 2023.
Case 3: Medipal Holdings and Sumitomo Pharma Food & Chemical (2023) — A carve-out of a drugmaker’s non-pharmaceutical business
In November 2022, Sumitomo Pharma agreed to sell all shares of Sumitomo Pharma Food & Chemical (Kita-ku, Osaka), its subsidiary dealing in food ingredients, food additives and chemical materials, to Medipal Holdings, and completed the sale on March 31, 2023. The equity value was set at ¥43.5bn (~USD 290mn), and the sale price was that amount less a special dividend paid by the target to Sumitomo Pharma before the transfer. The target’s revenue for the fiscal year ended March 2022 was ¥33.5bn (~USD 223mn). Sumitomo Pharma aimed to concentrate on pharmaceuticals by separating its non-pharmaceutical business, and expected a gain of about ¥25bn (~USD 167mn). Medipal stated that it would apply the target’s R&D capabilities and products through its own distribution network and overseas operations. After the acquisition, the target was renamed MP Gokyo Food & Chemical.
This transaction shows that (i) a drugmaker sold a non-pharmaceutical subsidiary to a pharmaceutical wholesaler to concentrate on its core business, (ii) a wholesale major extended into food ingredients and chemicals adjacent to ethical drugs, and (iii) both the seller and the buyer disclosed the purpose and the basis of the price.
Case 4: Medius Holdings and Makoto Medical Seiki (2024), Sano Kikai (2021) — A listed dealer acquiring regional dealers
In October 2023, Medius Holdings reached a basic agreement to acquire Makoto Medical Seiki, a medical device dealer in Chuo, Yamanashi. Makoto was established in September 1947; 99.58% of its shares were held by Makoto Holdings, the owner’s holding company; and it reported revenue of ¥7.1bn (~USD 47mn) and a net loss of ¥21mn for the fiscal year ended April 2023. Medius signed a share purchase agreement in February 2024, acquired 65% in March for ¥306mn (~USD 2.0mn), and acquired 100% in April. Medius cited a larger share of the Yamanashi market and stronger product procurement.
In October 2021, Medius also acquired all shares of Sano Kikai (established in 1973), a medical device dealer in Minami-ku, Kyoto, from its president, who held 79.7%, and other shareholders. Sano Kikai’s revenue for the fiscal year ended June 2021 was ¥3.1bn (~USD 21mn). Medius cited the expansion of its sales territory, the strengthening of its business base, and Sano Kikai’s strength in endoscopy products.
This transaction shows that (i) a listed dealer has expanded its territory by acquiring prefecture-level regional dealers from their owners, (ii) a company reporting a net loss was acquired, with the acquirer citing a larger share of the Yamanashi market and stronger procurement of its own, and (iii) the acquisition was staged, with a majority bought for cash before the remaining shares were acquired.
Case 5: Olba Healthcare Holdings and DVx (September 2026) — A combination of two listed dealers
On May 22, 2026, Olba Healthcare Holdings of Okayama and DVx, a Tokyo-based dealer in cardiovascular products such as pacemakers and catheters, signed a share exchange agreement for a management integration. DVx shareholders received 0.5 Olba shares for each DVx share; DVx was delisted on August 28, and the share exchange took effect on September 1, 2026. On the same day, Olba Healthcare Holdings changed its name to Olba DVx Healthcare. The two companies had reached a basic agreement on a business alliance in October 2022 and signed an alliance agreement in March 2023.
The companies cited repeated reimbursement cuts, rising logistics costs, deteriorating hospital finances and progressing industry consolidation as the background. They set out synergies in five areas: complementary territories in Kanto (DVx) and Chugoku-Shikoku (Olba) together with stronger purchasing; the rollout of in-house products; integrated logistics in Chugoku-Shikoku and shared use of a logistics center; common logistics systems and product master data; and personnel exchange. At announcement, Olba’s revenue was ¥122.7bn (~USD 818mn) for the fiscal year ended June 2025, and DVx’s was ¥56.0bn (~USD 373mn) for the fiscal year ended March 2026.
This transaction shows that (i) two listed dealers with different home territories combined through a share exchange after a business alliance, (ii) a dealer handling medical materials and general medical devices was combined with a specialist cardiovascular dealer, and (iii) the expected synergies were set out by territory, purchasing, logistics and systems.
Case 6: Medical Ikkou Group and small regional wholesalers (2024–2026) — Successive acquisitions of small wholesalers
Medical Ikkou Group of Tsu, Mie, a listed company whose main business is dispensing pharmacies, acquired all shares of Sato Yakuhin Hanbai of Kawaguchi, Saitama (established in 1981; revenue of ¥1.89bn, ~USD 13mn, for the fiscal year ended June 2024) from four individual shareholders in October 2024. It went on to acquire Wakamatsu Yakuhin (Takamatsu), Keiyo Sawai Yakuhin (Chiba Prefecture), Kochi Daiichi Yakuhin (Kochi; acquired in May 2025) and Saito Yakuhin (acquired in July 2025), and merged the acquired companies into its subsidiary Medical Ikkou. In April 2026, it acquired the pharmaceutical wholesale division of Nisshin Yakuhin of Saga (revenue of ¥875mn, ~USD 5.8mn) through a business transfer. Its acquisition of Shizuoka Sawai Yakuhin of Numazu was called off in April 2025.
The group stated that, with ethical drug prices set by the government and limited room to pass on costs, it would respond to changes in its environment through efficiency from greater scale.
This transaction shows that (i) a listed pharmacy operator that also runs a wholesale business has been a buyer for small wholesalers, including a company with revenue of ¥1.89bn and a wholesale division with revenue of ¥875mn, (ii) the deals took the form of both share acquisitions and transfers of wholesale divisions alone, and (iii) the stated rationale was efficiency from scale under government-set prices.
Case 7: Medirise Holdings and Akita Ika Kikaiten (2026, basic agreement) — A holding company of Tohoku dealers
In April 2024, three dealers, Shibata Intec (Sendai), Kyoritsu Ika Kikai (Morioka) and Legit Medical (Aomori), combined under Medirise Holdings (Sendai) through share exchanges. In October 2025, Medirise formed a business alliance with Akita Ika Kikaiten (established in 1966), a subsidiary of Medius, to strengthen supply and business continuity across the six Tohoku prefectures through shared use of logistics bases, and to improve procurement through closer ties with manufacturers.
On July 17, 2026, Medirise and Akita Ika Kikaiten signed a basic agreement to begin discussions on a management integration through a share exchange. The definitive agreement is scheduled for late October 2027, and the share exchange is scheduled to take effect on April 1, 2028. The companies cited population decline, shortages of medical personnel and changes in the logistics environment, and aim to build a stable and efficient supply system in Tohoku.
This transaction shows that (i) owner-run regional dealers combined under a holding company and created a platform for further integration, (ii) a listed dealer’s subsidiary is moving, after a business alliance, toward integration with another regional group, and (iii) about 1 year and 8 months is scheduled between the basic agreement and the effective date.
4. Foreign Capital in Japanese Pharmaceutical and Medical Distribution — Out-In Transactions
Foreign acquisitions of Japanese pharmaceutical wholesalers or general medical device dealers have not been identified in public disclosures within the scope of this article. Foreign companies have, however, entered adjacent fields: a manufacturer has acquired its exclusive Japanese distributor, a global dental distributor has invested in Japanese dealers, and foreign private equity funds have acquired companies in dispensing pharmacies and medical supplies manufacturing. Cases 8 to 11 below are all in fields adjacent to pharmaceutical wholesale and general medical device distribution.
Case 8: Straumann and Daishin Trading’s implant business (2007) — A manufacturer acquires its exclusive Japanese distributor
In July 2007, Swiss dental implant maker Straumann completed its acquisition of Daishin Implant System, the implant business of Osaka-based Daishin Trading, which had been Straumann’s exclusive distributor in Japan since 1984 and employed about 80 people. The consideration was CHF 75mn in cash plus a performance-based earn-out of up to CHF 10mn. Straumann stated that it would book all of its Japanese sales and profits, and that about 95% of group revenue would come through its own subsidiaries.
This transaction shows that (i) a foreign manufacturer acquired its long-standing exclusive distributor’s business to take direct control of sales in Japan, and (ii) the transaction covered the business run as the exclusive distributor and its approximately 80 employees.
Case 9: Henry Schein, Iwase Dental Supply (2014) and One Piece (2016) — A global distributor enters Japan through investments
Henry Schein, a US-based distributor of dental and medical products, entered Japan in October 2014 with an investment in Iwase Dental Supply, a full-service dental dealer serving the greater Tokyo area. In March 2016, it announced that it would take a 50% interest in One Piece, a subsidiary of the dental equipment maker J. Morita comprising 8 regional dental dealers, including dealers in Nara, Nagoya, Sapporo and Sendai. One Piece served about 6,000 dental clinics and had sales of about USD 125mn in 2015. Henry Schein stated that, with One Piece, Henry Schein Japan would serve about 20% of the dentists in Japan, and that Kenichiro Iwase of Iwase Dental Supply would lead the expanded business. Financial terms were not disclosed.
This transaction shows that (i) a global distributor entered Japan through investments in regional dealers and a group of dealers rather than through a single full acquisition, (ii) it partnered with a Japanese manufacturer by taking a 50% interest in that manufacturer’s dealer subsidiary, and (iii) the management of a Japanese dealer led the combined business.
Case 10: CVC and Sogo Medical (2023 announcement) — A secondary buyout of a pharmacy and medical-support platform
In December 2023, CVC announced that its Asia fund would acquire 100% of Sogo Medical Group from Polaris Private Equity Fund V and other shareholders, with completion expected in mid-February 2024. Founded in 1978, Sogo Medical operated about 740 dispensing pharmacies across Japan at the time, alongside consulting for medical institutions, career and practice-opening support for doctors, medical equipment leasing, staffing and other services. Sogo Medical had been delisted from the Tokyo Stock Exchange in April 2020 through an MBO. CVC stated that it would integrate the medical support and dispensing pharmacy businesses with digital services. Sogo Medical has continued to acquire pharmacy operators, including Life Art (December 2024), PAC (June 2025) and Hitachinaka Yakugyo (June 2026), and reports 797 dispensing pharmacies as of October 1, 2026.
This transaction shows that (i) a Japanese healthcare services company taken private by a domestic fund was then sold to a foreign fund, and (ii) the acquired company has continued to serve as a platform for further acquisitions.
Case 11: Carlyle and Hogy Medical (2026) — A take-private of a medical supplies manufacturer
In December 2025, a vehicle controlled by Carlyle funds launched a tender offer for Hogy Medical, a maker of surgical kits and other medical supplies, at ¥6,700 (~USD 45) per share. Shareholders affiliated with Dalton Investments, holding 27.58%, agreed to tender. Carlyle cited the expansion of premium surgical kits, growth in Southeast Asia, and the development of Hogy’s operating-room management system into a broader hospital management platform. The tender offer closed on March 2, 2026 with 87.63% of voting rights, and Hogy Medical was delisted on May 15, 2026.
This transaction shows that (i) a foreign fund acquired a listed Japanese medical supplies company that sells to hospitals, and (ii) the stated growth plan included both domestic hospital services and expansion in Southeast Asia.
Foreign shareholders in listed wholesalers
Foreign investors have also become large shareholders of the wholesale majors, as described in Section 1. 3D Investment Partners, founded in 2015 and based in Singapore, held 24.66% of Toho Holdings’ voting rights as of February 3, 2026, and the dispute over Toho’s countermeasure was before the Tokyo District Court as of October 2026. Silchester International Investors announced that funds it manages held about 11.96% of Medipal’s issued shares as of September 1, 2026, and has requested an extraordinary general meeting; Medipal disclosed on October 13, 2026 that it had set a record date for an extraordinary general meeting. These are minority positions, not acquisitions, but they show that foreign capital already holds significant stakes at the top of the industry.
Lessons from these entries
In each of the four cases above, the foreign company entered through an established Japanese business with its own customers and people, rather than building one from scratch. In addition, in Case 9 the foreign distributor took partial stakes and partnered with a Japanese manufacturer and with the management of Japanese dealers. And in Case 10, the acquired company continued to acquire smaller operators after the change of ownership.
5. Japanese Pharmaceutical Distributors Abroad — In-Out Transactions
For overseas companies, Japanese pharmaceutical distributors and trading houses are potential acquirers of their businesses and potential partners. Their recent transactions show what they buy, in what form and, where disclosed, at what price. Within the scope of this article, overseas investments by Japanese pharmaceutical wholesalers and medical device dealers have mostly taken the form of joint ventures or preliminary agreements, and no control acquisition with a disclosed price has been identified. The one transaction with a disclosed price is a trading house’s acquisition of a drugmaker’s sales business (Case 12).
Case 12: Marubeni and Sumitomo Pharma’s Asian business (completed July 2025) — A trading house acquires a pharmaceutical sales business
In April 2025, Marubeni announced that it would acquire 60% of a new company holding Sumitomo Pharma’s pharmaceutical sales business in China, Taiwan, Hong Kong and Southeast Asia for about ¥45bn (~USD 300mn), with an option to acquire the remaining 40% for about ¥27bn (~USD 180mn) from 2029. The business was expected to generate revenue of ¥45.8bn (~USD 305mn) and core segment profit of ¥23.1bn (~USD 154mn) for the fiscal year ended March 2025. The acquisition was completed on July 31, 2025, and Sumitomo Pharma booked a gain of ¥49bn (~USD 327mn). Marubeni cited the long-term growth of Asia’s pharmaceutical market and the supply system, track record and trust that Sumitomo Pharma had built, and set a target of more than ¥100bn (~USD 667mn) in pharmaceutical-related sales by fiscal 2029. Scaling the price for 60% to 100% gives about ¥75bn (~USD 500mn), about 3.2 times the core segment profit disclosed by Sumitomo Pharma (a simple calculation by Syntax Partners; including the option price for the remaining 40%, the total is about ¥72bn, ~USD 480mn). Core segment profit is a measure used by Sumitomo Pharma and accounted for about half of the business’s revenue, so the multiple is not directly comparable with valuations of wholesalers whose operating margins are about 1%.
This transaction shows that (i) a Japanese drugmaker carved out its overseas sales business and the buyer was a Japanese trading house, (ii) the buyer acquired a majority first, with an option on the remainder, and (iii) the buyer disclosed both the price and the profit of the business acquired.
Case 13: Alfresa Holdings in Vietnam and with Ai Ken Pharma (2013 onward) — Import and distribution in Southeast Asia
In November 2013, Alfresa Holdings established a joint venture with Codupha, a Vietnamese pharmaceutical wholesaler. The joint venture imports and sells medical devices, medical materials and diagnostic reagents in Ho Chi Minh City. In September 2025, Alfresa signed a basic agreement to begin discussions on a capital and business alliance with Singapore-based Ai Ken Pharma Asia Pacific Holdings, which handles the import and distribution of pharmaceuticals in Cambodia and Laos. Alfresa stated that it aims to build a business in Southeast Asia that handles registration, import, distribution and sales promotion on behalf of pharmaceutical makers, and to help Japanese pharmaceutical makers secure sales channels in the region. It described the impact on its earnings as minimal.
This transaction shows that (i) a wholesale major is expanding abroad through a joint venture and alliance discussions, and (ii) its aim is to provide distribution functions for Japanese pharmaceutical makers’ products outside Japan.
Case 14: Olba Healthcare Holdings and THAI OLBA Healthcare (2023) — A regional dealer’s joint venture in Thailand
In January 2023, Olba Healthcare Holdings started operations at THAI OLBA Healthcare in Pathum Thani, Thailand, as a joint venture with Thai individual shareholders. Olba holds 49.0% of the voting rights and treats it as a consolidated subsidiary. THAI OLBA Healthcare imports and sells Japanese-made medical devices and handles regulatory filings in Thailand. Olba’s long-term vision includes earning 20% of its operating profit overseas. THAI OLBA Healthcare had a capital deficit of ¥155mn (~USD 1.0mn) as of March 31, 2026.
This transaction shows that (i) a listed dealer based in Chugoku-Shikoku is expanding abroad through a joint venture, and (ii) the overseas business is at an early stage and has accumulated losses.
6. Industry-Specific Factors Examined by Acquirers
In acquisitions of Japanese pharmaceutical wholesalers and medical device dealers, acquirers examine industry-specific factors in addition to financials. Based on the purposes and synergies disclosed by the acquirers in the cases above, these factors fall into three groups.
- Territory and customers — Which regions the company serves, and which hospitals, clinics and pharmacies it supplies. The acquirers cited their business base in Kyushu (Case 1), in Nagasaki and Saga (Case 2), market share in Yamanashi (Case 4), complementary territories in Kanto and Chugoku-Shikoku (Case 5), and supply across the six Tohoku prefectures (Case 7). Whether the target’s territory overlaps with or complements the acquirer’s determines the expected synergies.
- Products and suppliers — Which clinical fields and material types the company is strong in, and which manufacturers it deals with. Stronger procurement and endoscopy products were among the reasons in Case 4, and cardiovascular expertise and purchasing power in Case 5. As Case 8 shows, an exclusive distribution agreement with a manufacturer can itself be the subject of the transaction.
- Logistics and supply — Logistics bases, inventory and logistics systems, handling of products in short supply, and business continuity in disasters. Integrated logistics and common systems and product master data were among the synergies in Case 5. In Case 7, the 2025 business alliance set out shared logistics bases and stronger business continuity, and the integration talks aim at a stable supply system in Tohoku. The acquirer in Case 6 cited efficiency from scale.
7. Implications for Overseas Acquirers
Target universe
In Japan pharmaceutical distribution M&A, the targets in the cases above were owner-run regional wholesalers and dealers (Cases 1, 4 and 6), companies already linked to the acquirer through an alliance (Cases 2 and 5), and subsidiaries of pharmaceutical makers or other groups (Case 3 and Active Medical). In regional pharmaceutical wholesale, the buyers were the wholesale majors (Cases 1 and 2) and, for small wholesalers, a listed pharmacy operator with a wholesale business (Case 6). In medical device distribution, listed dealers and regional holding companies are consolidating prefecture-level dealers. Foreign entries to date have been in adjacent fields, through exclusive distributors, dealer groups and platform companies (Cases 8 to 11). Identifying owner-run targets requires research beyond public databases, and approaching them requires direct contact with owners or parent companies, in Japanese.
Transaction structures
The cases show several structures: full acquisitions from an owner’s holding company after non-core businesses are moved out (Case 1), a business alliance and minority stake followed by a share exchange (Case 2), a carve-out with a pre-closing special dividend (Case 3), a majority bought for cash before the remaining shares (Case 4), a share exchange between two listed companies (Case 5), transfers of a wholesale division alone (Case 6), integration under a regional holding company (Case 7), and a 50% interest in a dealer subsidiary of a Japanese manufacturer (Case 9). The appropriate structure depends on the intentions of the owner or parent company and on the acquirer’s integration plan.
What sellers emphasize
Parent-company sellers explained their decisions in terms of their own focus: Sumitomo Pharma separated its non-pharmaceutical business to concentrate on pharmaceuticals (Case 3). In the regional integrations, the parties stressed supply: Olba and DVx cited the pressures on hospitals and logistics (Case 5), and Medirise and Akita Ika Kikaiten aim to build a stable and efficient supply system in Tohoku (Case 7). Individual owner-sellers in these cases did not disclose their reasons. These statements suggest that, in this sector, plans for continued supply to hospitals and pharmacies are part of what sellers and integration partners weigh alongside the price.
8. Syntax Partners
Syntax Partners is a Japan-based M&A advisory firm that acts solely as financial advisor. In any transaction, we advise one side only, either the buyer or the seller. We advise on Japan pharmaceutical distribution M&A, including pharmaceutical wholesale and medical device distribution, in both domestic and cross-border transactions.
Buy-side advisory
For foreign companies considering acquisitions or capital alliances in Japan, we support the full process: mapping targets based on their strategy, including non-listed owner-run companies and businesses within Japanese corporate groups; approaching owners and parent companies directly; negotiation; and execution. We work in Japanese and English, among other languages.
Sell-side advisory
As an advisor that maximizes the interests of sellers and owners, we support Japanese owners and parent companies considering a sale or business succession. The buyer universe we cover includes not only Japanese wholesale majors and listed dealers but also regional peers, adjacent-industry companies, private equity, and overseas strategic buyers such as manufacturers and distributors. Our transaction support draws on our understanding of the industry, including a company’s relationships with regional hospitals and pharmacies, its agreements with manufacturers, and its logistics and supply operations.
Selected engagements are listed in our Track Record.
We welcome discussions at any stage, from early-stage exploration of acquisitions or partnerships in Japan to live transactions.
This article was prepared by Syntax Partners, Inc. based on public information, including companies’ official announcements, IR materials, and materials published by government agencies and industry associations.